Decrease in exhaled hydrogen as marker of congestive heart failure
Atsushi Shibata(Keio University), Toshihisa Anzai(Hokkaido University), Satoshi Yasuda(Tohoku University), Takeshi Aiba(National Cerebral and Cardiovascular Center), Hideshi Okada(Gifu University), Hideaki Kanzaki(National Cerebral and Cardiovascular Center), Hisao Ogawa(Kumamoto University Hospital), Tetsuro Yokokawa(Fukushima Medical University), Naoya Jinno(National Cerebral and Cardiovascular Center), Hatsue Ishibashi‐Ueda(United Cerebral Palsy), Yoshihiko Ikeda(National Cerebral and Cardiovascular Center), Kengo Kusano(Northwestern University), Keiko Ohta‐Ogo(National Cerebral and Cardiovascular Center), Akito Shimouchi(National Cerebral and Cardiovascular Center), Mikiyasu Shirai(National Cerebral and Cardiovascular Center), Yasuo Sugano(keiyu Hospital)
Cited by 8
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.
|Circulation|1994|1.3k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|755